India has announced a package to support the accelerated development of indigenous COVID-19 vaccines.




  • 1 harmful
  • 0 neutral
  • 0 liberalising


Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development

Request for Expression of Interests (REOI)

Augmentation of Manufacturing Capacity for COVAXIN production under Mission COVID Suraksha

Government Supports Augmentation of Manufacturing Capacity for COVAXIN production under Mission COVID Suraksha

Union Ministry of Health finalises advance arrangement with M/s Biological-E Ltd., Hyderabad for 30 cr COVID19 Vaccine doses

Inception date: 29 Nov 2020 | Removal date: 28 Nov 2021

Financial grant

On 29 November 2020, the Government of India announced an INR 900 crore (USD 121 million)* fund for accelerating the development of COVID-19 vaccines. The package titled "Mission COVID Suraksha - The Indian COVID-19 Vaccine Development Mission" will provide grants for supporting various stages of vaccine development from preclinical development, clinical development, to manufacturing and regulatory facilitation for deployment. 

The INR 900 crore fund has been announced for the Phase-I of this program and is planned for 12 months. The program aims to support approximately 5 to 6 such vaccine candidates.

The Department of Biotechnology (appointed to run the program) published several Request for Expression of Interest (REOI) documents in December 2020 and June 2021 for providing grants for capacity development and for human clinical trials of COVID-19 vaccines. According to these documents, the funding support shall be provided to companies with at least 51% Indian ownership, partnerships with a minimum of half Indian partners, research institutes of Indian universities only, or organizations or non-profit entities that have at least half Indian members.

On 16 April 2021, the Ministry of Science and Technology through a Press Release notified that from the Mission COVID Suraksha fund a grant of approximately INR 65 crore (~ USD 8.79 million)* to Bharat Biotech Limited and Haffkine Biopharmaceutical Corporation Limited each and a grant of INR 60 crore (~ USD 8.12 million) to Indian Immunologicals Limited. Bharat Biotech Limited is a private limited company while the latter two are public sector enterprises.

On 15 May 2021, the Ministry specified in a press release that a grant of INR 30 crore (~ USD 4.06 million) will also be provided to Bharat Immunologicals and Biologicals Limited (BIBCOL), a central public sector enterprise.

On 3 June 2021, the Ministry of Health and Family Welfare specified in a press release that a grant-in-aid of INR 100 crore (~ USD 13.52 million) was provided to Biological-E Limited for the development of its vaccine.

* INR to USD as of 29 November 2020 - INR 73.92/USD